Equillium (EQ) Q1 2026 earnings summary

Executive summary

• Advanced EQ504 as lead candidate with Phase 1 proof-of-mechanism study set for mid-2026 and data expected six months later.

• No product sales to date; operations funded by equity and debt financings, with a $221.5 million accumulated deficit as of March 31, 2026.

• Completed $35 million private placement in March 2026 and $30 million in August 2025, with a potential $20 million milestone tranche.

• Appointed Snehal Naik, Ph.D., as Chief Development Officer to lead clinical and medical strategy.

Financial highlights

• Net loss for Q1 2026 was $5.3 million, an improvement from $8.7 million in Q1 2025.

• Research and development expenses decreased to $3.0 million from $5.9 million year-over-year, mainly due to the wind down of clinical studies.

• General and administrative expenses fell to $2.6 million from $2.9 million year-over-year.

• Cash and cash equivalents totaled $61.3 million as of March 31, 2026, up from $30.3 million at year-end 2025.

• Weighted-average shares outstanding increased to 96.3 million from 35.6 million year-over-year due to equity financings.

Outlook and guidance

• Cash runway expected to fund operations into 2029, assuming current plans and estimates.

• Phase 1 EQ504 study planned for mid-2026, with data anticipated six months later.

• No revenue from product sales expected in the next 12 months; future funding needs anticipated for further development and commercialization.

• Continued evaluation of EQ302 for gastrointestinal indications, including celiac disease.